Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Saltz
    Saltz
  4. O'Reilly
    O'Reilly
  5. Abou-Alfa
    Abou-Alfa
  6. Scher
    Scher
  7. Kris
    Kris
  8. Hudis
    Hudis
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (1998)
  2. Solid Tumor Oncology Division (1627)
  3. Gastrointestinal Oncology Service (390)
  4. Genitourinary Oncology Service (367)
  5. Thoracic Oncology (336)
  6. Survivorship Research (329)
  7. GSK Faculty (305)
  8. Division of Subspecialty Medicine (288)
  9. Hematologic Malignancies, Division of (267)
  10. Breast Medicine Service (247)
Search Within
  1. "Department of Medicine"
Formats
  1. Meeting Abstract (1199)
  2. Journal Article (705)
  3. Review (28)
  4. Editorial (23)
  5. Guidelines (15)
  6. Correspondence (12)
  7. Book Section (10)
  8. Conference Paper (5)
  9. Research Letter (1)
Groups
  1. Department of Medicine (1998)
  2. Solid Tumor Oncology Division (1627)
  3. Gastrointestinal Oncology Service (390)
  4. Genitourinary Oncology Service (367)
  5. Thoracic Oncology (336)
  6. Survivorship Research (329)

More Groups

People
  1. Alexander Drilon (110)
  2. Robert Motzer (99)
  3. Leonard Saltz (67)
  4. Eileen O'Reilly (60)
  5. Ghassan Abou-Alfa (55)
  6. Matthew Hellmann (52)

More People

Years
  1. 2025 (22)
  2. 2024 (180)
  3. 2023 (170)
  4. 2022 (189)
  5. 2021 (179)
  6. 2020 (168)

More Years

Publications
  1. Annals of Oncology (1393)
  2. JNCI: Journal of the National Cancer Institute (181)
  3. Neuro-Oncology (95)
  4. Clinical Infectious Diseases (93)
  5. JNCI Cancer Spectrum (27)
  6. Journal of Infectious Diseases (19)

More Publications

Results (1998)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
    Meeting Abstract

    Shoushtari, A. N.; Middleton, M. R.; Hamid, O.; Meier, F.; Bauer, T.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
    Meeting Abstract

    Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
    Meeting Abstract

    Patel, S.; McKean, M.; Piperno-Neumann, S.; Shoushtari, A. N.; Hernandez-Aya, L.; Orloff, M.; Khan, S.; Montazeri, K.; Kapiteijn, E.; Buchbinder, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
    Meeting Abstract

    Heredia, J. B.; Diplas, B. H.; El Nahhas, O. S. M.; Selenica, P.; Pareja, F.; Mandelker, D.; Weigelt, B.; Riaz, N.; Rosen, E.; Sfeir, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
    Meeting Abstract

    Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
    Meeting Abstract

    Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
    Meeting Abstract

    McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
    Meeting Abstract

    Burton, E.; Milton, D.; Simpson, L.; Tetzlaff, M.; Glitza, I. C.; Ross, M. I.; Gershenwald, J. E.; McQuade, J.; Wong, M.; Patel, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
    Meeting Abstract

    Nabell, L.; Ho, A. L.; Posner, M. R.; Neupane, P.; Naqash, A. R.; Wong, S.; Niu, J. J.; Pearson, A. T.; Laux, D.; Adkins, D. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
    Meeting Abstract

    Garcia, V. M.; Calvo, E.; Asch, A.; Butler, M.; Zugazagoitia, J.; Charlson, J.; Cervantes, A.; Van Tine, B.; Aggen, D.; Clarke, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save